Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

MISSION Therapeutics Strengthens Board

Published: Monday, October 01, 2012
Last Updated: Monday, October 01, 2012
Bookmark and Share
Appointments of Michael Moore and Fritz Frickel as Executive Chairman and Non-Executive Director respectively.

MISSION Therapeutics has announced the appointment of Dr Michael Moore as Executive Chairman and Fritz Frickel as Non-Executive Director.

Graziano Seghezzi of Sofinnova partners, on behalf of the investor syndicate, commented: “We warmly welcome Michael Moore and Fritz Frickel to the MISSION Board. Their combined commercial, drug translational and managerial experience will complement our existing capabilities and provide valuable links with the pharma and venture capital industries with which they have both enjoyed highly productive relationships”.

Dr Moore brings extensive experience to MISSION at a formative phase of the company’s development.

Following an earlier academic career principally at the Paterson Institute for Cancer Research (University of Manchester), Dr Moore has more than two decades of senior management experience in the biotechnology sector, as Chief Scientific Officer of Xenova Group plc and more recently as Chief Executive Officer of Piramed, the UK bioscience company acquired by F Hoffmann-La Roche in 2008.

Dr Moore also serves as a Non-Executive Director of several companies including PsiOxus Therapeutics. He is also a member of the Cancer Research UK Science Committee.

Dr Fritz Frickel joins the MISSION Board as a non-executive director. Currently an independent advisor to venture capital firms, biotech start-ups and universities, Dr Frickel was formerly Senior Vice-President of R&D and acting CEO of Alantos which was acquired by Amgen.

Other senior pharma roles have included SVP of research at Abbott, world-wide head of research at BASF and head of clinical, pharmaceutical and regulatory development at Knoll.

Dr Frickel served as non-executive director of RespiVert, an Imperial College spin-out, until its acquisition by Janssen Biotech Inc. in 2010 and is currently a director of new start-up company TopiVert.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,600+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

MISSION Secures £20 million ($32 million) in Series B Financing
Pfizer Venture Investments join MISSION investor syndicate to advance compounds through preclinical development for genetically-defined cancers.
Tuesday, November 19, 2013
Biomedical Catalyst Feasibility Award to Tackle Drug-resistant Ovarian Cancer
Feasibility award granted by Technology Strategy Board to identify DUBs.
Tuesday, September 17, 2013
Appointment of Associate Faculty Member at Sanger Institute
MISSION Co-Founder and CSO, Professor Steve Jackson appointed as Faculty Member.
Monday, April 08, 2013
Scientific News
RNAi Screening Trends
Understand current trends and learn which application areas are expected to gain in popularity over the next few years.
Long-sought Discovery Fills in Missing Details of Cell 'Switchboard'
A biomedical breakthrough reveals never-before-seen details of the human body’s cellular switchboard that regulates sensory and hormonal responses.
Tracking Breast Cancer Before it Grows
A team of scientists led by University of Saskatchewan researcher Saroj Kumar is using cutting-edge Canadian Light Source techniques to screen and treat breast cancer at its earliest changes.
New Mussel-Inspired Surgical Protein Glue
Korean scientists have developed a light-activated, mussel protein-based bioadhesive that works on the same principles as mussels attaching to underwater surfaces and insects maintaining structural balance and flexibility.
Web App Helps Researchers Explore Cancer Genetics
Brown University computer scientists have developed a new interactive tool to help researchers and clinicians explore the genetic underpinnings of cancer.
Researchers Develop Vaccine that Protects Primates Against Ebola
A collaborative team from The University of Texas Medical Branch at Galveston and the National Institutes of Health have developed an inhalable vaccine that protects primates against Ebola.
Nanoparticles Can Clean Up Environmental Pollutants
Researchers have found that nanomaterials and UV light can “trap” chemicals for easy removal from soil and water.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
AncestryDNA and Calico to Research the Genetics of Human Lifespan
Collaboration will analyze family history and genetics to facilitate development of cutting-edge therapeutics.
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,600+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!